Under the partnership, the Pfizer INDovation program will empower DPIIT-recognized startups with grants of up to Rs. 60 lakhs each, along with a tailored 18-month incubation program delivered by Social Alpha
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
Inclacumab was generally well tolerated in THRIVE-131
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Subscribe To Our Newsletter & Stay Updated
